Blog

Seeing a company’s projected sales growth instantly tells you what the outlook is for their products and services. As a point of reference, over the last 10 years, the median sales growth for the stocks in the S&P 500 was 14%. Of course, different industries will have different growth rates that are considered good.

• On corrections down, there will be some support from the lines at $38.66 and $36.15.
• There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
• 36.35% during the next 3 months and, with a 90% probability hold a price between $53.17 and $57.04 at the end of this 3-month period.

https://1investing.in//sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues. Earnings estimate revisions are the most important factor influencing stocks prices. It’s an integral part of the Zacks Rank and a critical part in effective stock evaluation. If a stock’s EPS consensus estimate is $1.10 now vs. $1.00 the week before, that will be reflected as a 10% change. If, on the other hand, it went from $1.00 to 90 cents, that would be a -10% change in the consensus estimate revision.

Stock Quote

It’s economy of greece by multiplying the current market price by the total number of shares outstanding. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.99 and a quick ratio of 2.90. The firm has a market cap of $1.89 billion, a PE ratio of 22.43 and a beta of 0.76.

• The company has a 50-day moving average of $34.71 and a two-hundred day moving average of $31.00.
• Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.
• That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
• Amphastar Pharmaceuticals has received no research coverage in the past 90 days.
• Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
• The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.4 by $0.33.

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 13, 2023, there were 0 analysts who downgraded Amphastar Pharmaceuticals Inc’s stock and 2 analysts who upgraded over the last month. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance.

About the Amphastar Pharmaceuticals, Inc. stock forecast

A ratio under 40% is generally considered to be good.But note; this ratio can vary widely from industry to industry. So be sure to compare it to its group when comparing stocks in different industries. A higher number means the company has more debt to equity, whereas a lower number means it has less debt to equity. A D/E ratio of 1 means its debt is equivalent to its common equity.

The tested combination of price performance, and earnings momentum , creates a powerful timeliness indicator to help you identify stocks on the move so you know when to get in and when to get out. Stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange . Companies can be purchased through major U.S. brokerages in the form of American Depository Receipts , which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.32 between high and low, or 3.37%. For the last week, the stock has had daily average volatility of 2.79%.

Company Information

The financial health and growth prospects of AMPH, demonstrate its potential to underperform the market. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F. 3 brokers have issued 1-year price targets for Amphastar Pharmaceuticals’ stock. Their AMPH share price forecasts range from $36.00 to $44.00. On average, they expect the company’s stock price to reach $40.75 in the next twelve months.

One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Our testing substantiates this with the optimum range for price performance between 0-20. The Amphastar Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.

52 week high is the highest price of a stock in the past 52 weeks, or one year. Amphastar Pharmaceuticals Inc 52 week high is $44.46 as of April 11, 2023. One share of AMPH stock can currently be purchased for approximately $40.19. 61.72% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products.

Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

This is also commonly referred to as the Asset Utilization ratio. If a company’s net margin is 15%, for example, that means its net income is 15 cents for every $1 of sales the company makes. A change in margin can reflect either a change in business conditions, or a company’s cost controls, or both.

There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Amphastar Pharmaceuticals finds support just below today’s level at $36.56. If this is broken, then the next support from accumulated volume will be at $36.29 and $35.43. 36.35% during the next 3 months and, with a 90% probability hold a price between $53.17 and $57.04 at the end of this 3-month period. In total, 433 thousand shares were bought and sold for approximately $17.41 million.

ROE values, like other values, can vary significantly from one industry to another. The Historical Cash Flow Growth is the longer-term (3-5 year annualized) growth rate of the cash flow change. Once again, cash flow is net income plus depreciation and other non-cash charges. Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. According to 11 analysts, the average rating for AMPH stock is “Buy.” The 12-month stock price forecast is $42.08, which is an increase of 4.70% from the latest price.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today. Over the last year, Amphastar Pharmaceuticals Inc has hit prices as high as $44.46 and as low as $26.76. Year to date, Amphastar Pharmaceuticals Inc’s stock is up 59.73%. VTVT, MTEX, and BBI are the stocks whose asset turnover ratios are most correlated with AMPH. Over the past 106 months, AMPH’s EV/EBIT ratio has gone down 12.

Investors should consider their investment objectives and risks carefully before investing. It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum. Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value.

According to analysts’ consensus price target of $40.00, Amphastar Pharmaceuticals has a forecasted downside of 0.5% from its current price of $40.19. Amphastar Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Represents the company’s profit divided by the outstanding shares of its common stock. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products.

Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) are strong. Amphastar Pharmaceuticals saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 1,460,000 shares, a decrease of 16.6% from the February 28th total of 1,750,000 shares.

Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. The 1 week price change reflects the collective buying and selling sentiment over the short-term. A strong weekly advance is a sought after metric for putting potential momentum stocks onto one’s radar.